# Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE

> **NCT00461630** · PHASE3 · COMPLETED · sponsor: **University of Oxford** · enrollment: 25673 (actual)

## Conditions studied

- Cardiovascular Disease
- Peripheral Arterial Disease
- Diabetes Mellitus
- Coronary Heart Disease

## Interventions

- **DRUG:** ER niacin/laropiprant
- **DRUG:** simvastatin
- **DRUG:** ezetimibe/simvastatin

## Key facts

- **NCT ID:** NCT00461630
- **Lead sponsor:** University of Oxford
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 25673 (ACTUAL)
- **Last updated:** 2014-02-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00461630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00461630, "Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00461630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*